newsfilter
← Latest News
GlobeNewswire·

Celldex Initiates Phase 2 Study of Barzolvolimab in Atopic Dermatitis

HAMPTON, N.J., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that the Company has initiated a Phase 2 study of barzolvolimab in atopic dermatitis (AD) and that the study is